Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

A. Konkle, Barbara; Stasyshyn, Oleksandra; Chowdary, Pratima; Bevan, David; Mant, Tim; Shima, Midori; Engl, Werner; Dyck-Jones, Jacqueline; Fuerlinger, Monika; Patrone, Lisa; M. Ewenstein, Bruce; E. Abbuehl, Brigitt

doi:10.1182/blood-2015-03-630897

Public

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Published in Blood • Jul 8, 2015

Authors:

Barbara A. Konkle

Oleksandra Stasyshyn

Pratima Chowdary

Abstract

Current management of hemophilia A includes prophylaxis with factor VIII (FVIII) replacement every 2 to 3 days. BAX 855, Baxalta's pegylated full-length recombinant FVIII (rFVIII), was designed to increase half-life and, thus, reduce the frequency of prophylactic infusions while maintaining hemostat...

Subject

Adverse effect

Medicine

Recombinant DNA

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!